Sharemaestro Newsreel

Bristol Myers Squibb Company $BMY Shares Sold by Empowered Funds LLC

Empowered Funds LLC significantly reduced its stake in Bristol Myers Squibb Company (NYSE:BMY) by 38.0% during the first quarter, selling 210,880 shares and leaving them with 344,513 shares valued at over $20 million. Other institutional investors like Swiss RE Ltd., Darwin Wealth Management LLC, …

AbbVie wins EU clearance for Rinvoq as first systemic treatment for non-segmental vitiligo (ABBV:NYSE)

AbbVie announced that the European Commission has approved Rinvoq for the treatment of adult and adolescent patients aged 12 years and older with non-segmental vitiligo, who are candidates for systemic therapy. This approval marks Rinvoq as the first systemic treatment of its kind for …

Biogen Inc (BIIB) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Biogen Inc (BIIB), indicating its current valuation score of 8.73, ranking it 73rd out of 155 in the Pharmaceuticals industry. It highlights the company's P/E ratio of 21.99, which is significantly below its recent high but above …

Amgen Inc. $AMGN Stock Position Reduced by Amundi

Amundi decreased its ownership in Amgen Inc. (NASDAQ:AMGN) by 0.6% in the first quarter, selling 19,639 shares but still holding over 3.3 million shares worth $1.18 billion. While Amundi reduced its stake, other institutional investors like Parvin Asset Management and EverSource Wealth Advisors boosted …

Novo Nordisk (NYSE:NVO) Stock Looks Undervalued On Cash Flow And Earnings

Amarin (NASDAQ:AMRN) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Amarin's Q2 Earnings Beat Estimates, Revenues Fall Short

Amarin's VASCEPA Demand Rises 59% Globally; U.S. Share Hits 48%

Grifols shares jump after Q2 results exceed expectations

Biogen (BIIB) Earnings Date and Reports 2026 $BIIB

EU Approves AbbVie's RINVOQ After Trials Show Complete Scalp Hair Regrowth

The European Commission has approved AbbVie's RINVOQ (upadacitinib) for treating severe alopecia areata in adults and adolescents aged 12 and older. This approval is supported by Phase 3 trials where RINVOQ demonstrated significant scalp hair regrowth, including complete regrowth in some patients, at both …

Merck & Co., Inc. (MRK) Projected to Announce Quarterly Earnings on Tuesday

Merck & Co., Inc. (MRK) is expected to announce its Q2 2026 earnings before market open on Tuesday, August 4th, with analysts forecasting a loss of $0.26 per share on revenues of $16.35 billion. The company had previously beaten Q1 2026 estimates, reporting a …

Pfizer Number of Employees 2026 | Employee Count & Headcount Data

Pfizer Inc. had approximately 75,157 employees worldwide as of March 2026, marking an 8.3% decline from 2023. Despite the overall headcount reduction, Pfizer is actively hiring, with 2,887 active job postings in 2026, a 49.7% increase from the previous year. The company's workforce is …

Bristol Myers Squibb Hopes to Boost Drug Trials with NVIDIA Supercomputer

Bristol Myers Squibb (BMS) is set to become the first life sciences company to acquire NVIDIA's latest generation supercomputer, the NVIDIA DGX SuperPOD with AIDGX Vera Rubin NVL72 systems. This move deepens a three-year partnership between the two companies, aiming to accelerate drug discovery …

Bristol Myers Squibb (BMY) Stock Still Looks Cheap After Fresh AI Drug Discovery News

Bristol Myers Squibb (BMY) has seen a 42.2% return over the past year, with a Discounted Cash Flow (DCF) model suggesting its intrinsic value is significantly higher than its current share price, implying it's undervalued by 48.1%. The company's expansion into AI-driven drug discovery …

Earnings To Watch: Bristol-Myers Squibb (BMY) Reports Q2 Results Tomorrow

Bristol-Myers Squibb (BMY) is set to report its Q2 earnings this Thursday before market open. The company previously beat revenue expectations but slightly missed full-year EPS guidance. Analysts generally anticipate a 6.3% year-over-year revenue decline this quarter, while investor sentiment for the pharmaceutical sector …

Grifols (GRFS) Q2 2026 Earnings Call Transcript

Grifols reported a solid first half of 2026, with group net revenue reaching €3.574 billion, a 2.6% constant currency growth driven primarily by its Biopharma division. The company is on track to meet its full-year 2026 guidance, emphasizing a "smart growth" strategy focused on …

AbbVie Announces Availability of ELAHERE® (mirvetuximab soravtansine) in Singapore for the Treatment of Platinum-Resistant Ovarian Cancer

AbbVie has announced the availability of ELAHERE (mirvetuximab soravtansine) in Singapore for treating platinum-resistant ovarian cancer. This antibody-drug conjugate (ADC) is the first and only one approved for patients with FRα-positive high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have undergone …

Johnson & Johnson lawsuit: J&J offers up to $5.5 billion to settle baby powder ovarian cancer suits

Johnson & Johnson has proposed a settlement of up to $5.5 billion to resolve approximately 76,000 U.S. lawsuits alleging that its talcum powder products caused ovarian cancer. The company maintains that the lawsuits lack scientific merit and that the settlement aims to bring closure …

Amgen Inc Stock (AMGN) Moved Up by 4.02% on Jul 28: What Signal Does It Send?

Amgen Inc (AMGN) saw a 4.02% increase in its stock price, driven by strong second-quarter earnings that surpassed estimates and positive clinical data for its obesity drug MariTide. Technical indicators suggest a buy signal, though clinical safety concerns about MariTide and high pipeline dependency …

Pfizer (PFE): Company Profile, Stock Price, News, Rankings

This article provides a company profile for Pfizer (PFE), detailing its business in developing medications and vaccines across various therapeutic areas, with a significant focus on oncology. It highlights key strategic moves such as the acquisition of Seagen and re-entry into the obesity market, …

Johnson & Johnson proposes $5.5 billion talc settlement to end marathon legal fight

Johnson & Johnson has offered a $5.5 billion settlement to resolve ongoing lawsuits alleging its talc products caused ovarian cancer. This proposal comes after a previous $9 billion settlement from a subsidiary was denied by a bankruptcy court judge. The company aims to put …

Gilead Sciences, Inc. Revenue Breakdown – BIVA:GILD

This article provides a revenue breakdown for Gilead Sciences, Inc. (BIVA:GILD), highlighting its top-performing segment and key regional contributions. Last year, the company generated 530.79 billion MXN, with the Human Immunodeficiency Virus segment accounting for 374.11 billion MXN and the United States being the …

Amgen Q2 Results: Earnings call set for Aug 4 with CEO Bradway

Amgen Inc. is scheduled to release its second-quarter 2026 financial results on August 4, 2026, after the U.S. financial markets close. CEO Robert A. Bradway will lead a conference call at 4:30 p.m. ET to discuss financial performance, strategic initiatives, and pipeline developments. Live …

Pfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing

Pfizer (PFE) closed up 2.35% at $25.25, outperforming the S&P 500. Investors are anticipating the company's Q3 earnings report on August 4, 2026, with analysts expecting a 12.82% year-over-year decline in earnings per share and a 1.39% decrease in revenue. The stock currently holds …

Gilead Sciences (GILD) Laps the Stock Market: Here's Why

Gilead Sciences (GILD) recently outperformed the stock market, closing up 2.91% while the S&P 500 gained only 0.21%. Over the past month, the stock has climbed 3.32%, surpassing the Medical sector's loss. The company is set to report earnings on August 4, 2026, with …

What Johnson & Johnson Stock Told You Before It Surged

Johnson & Johnson (JNJ) stock surged by 61% from late July 2025 to July 2026, outperforming the S&P 500 and most pharma peers. This growth was driven by its strong oncology segment and steady guidance raises, which were detectable in its financial reports a …

Is Gilead Sciences (GILD) Overvalued Following Its Trodelvy Europe Expansion Win?

Gilead Sciences (GILD) is under scrutiny after the European Medicines Agency's committee backed the use of its drug Trodelvy for certain breast cancer patients. Despite strong share price performance over the past year, the company's valuation is debated, with one narrative suggesting it's 1.7% …

AstraZeneca Number of Employees 2026 | Employee Count & Headcount Data

AstraZeneca PLC (AZN) had approximately 97,021 employees worldwide as of March 2026, representing a 13.5% growth from 2023 but a 0.7% decline year-over-year in 2026. The company is actively hiring, with 3,640 job postings in 2026, and its workforce is primarily concentrated in the …

AbbVie Inc (ABBV) director adds stock-equivalent units after 25.5% 12-week rise

The insider acquisition lands with the biopharma stock still in an active weekly trend, though latest volume ran below its 13-week average.

Jim Cramer: J&J talc settlement is good for a stock that has so much going for it already

Jim Cramer highlighted Johnson & Johnson's talc settlement as a positive development, helping to boost the stock to new highs. However, he emphasized that more compelling reasons exist to own J&J, such as its strong pharmaceutical and medical technology portfolio. The company's impressive drug …

Novo Nordisk’s ZEUS Trial Reaches Completion: What It Could Mean for NVO Investors

Novo Nordisk's Phase 3 ZEUS trial, investigating ziltivekimab for cardiovascular outcomes in high-risk patients, has completed. This antibody aims to reduce heart events in individuals with atherosclerotic cardiovascular disease, chronic kidney disease, and systemic inflammation. The trial's success could expand Novo Nordisk's market beyond …

Grifols (BME:GRF) Starts Phase 3 Trials As Undervalued Narrative Faces A Fresh Test

Grifols has initiated two Phase 3 clinical trials for its immunoglobulin therapies, GAMUNEX-C and XEMBIFY, aiming to expand their U.S. labels despite recent stock declines but a 90-day gain. The company's shares are considered 31.6% undervalued with a fair value narrative of €14.40 compared …

AbbVie Inc. stock outperforms competitors on strong trading day

AbbVie Inc. (ABBV) stock advanced 2.45% to $263.20 on Tuesday, outperforming the S&P 500 Index and the Dow Jones Industrial Average. The company also reached a new 52-week high, exceeding its previous peak from the day before.

Johnson & Johnson agrees to pay $5.5 billion in talc powder settlement

Johnson & Johnson has agreed to a $5.5 billion settlement for lawsuits alleging its talc products caused ovarian cancer. This settlement is contingent on the participation of remaining claimants and follows a previous denial of a larger $9 billion settlement by a bankruptcy judge …

GSK: Healthy Results, But Limited Stock Upside (Rating Downgrade) (NYSE:GSK)

GSK reported healthy Q2 and H1 2026 results with core turnover and EPS growth at the upper end of guidance. However, the stock’s forward P/E and dividend yield offer limited upside, leading to a rating downgrade. Despite maintaining a long-term sales target, the projected …